Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Response to an ASX Price Query

March 30, 2016

Positive Results From Phase 2 Lumbar Fusion Trial

March 30, 2016

Phase 3 Meeting Set With FDA On Bone Marrow Regeneration

March 30, 2016

On Track for Phase 3 BMT Trial After Positive FDA Meeting

March 30, 2016

Novel Heart Attack Treatment Results Presented to US Forum

March 30, 2016

Mesoblast Targets Broader Cancer Indications

March 30, 2016

Mesoblast Clear To Proceed With Angioblast Acquisition

March 30, 2016

Appendix 4C and Clinical Trial Update

March 30, 2016

Revascor Increases Blood Supply to Damaged Heart Muscle

March 30, 2016

Mesoblast Included in S and P/ASX 200 Index

March 30, 2016

Key Product Franchises Featured at Nomura Asia Equity Forum

March 30, 2016

FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease

March 30, 2016

Cardiac Events, Mortality and Hospitalization Reduced

March 30, 2016

Appendix 4D and Half Year Financial Report to 31 Dec 2010

March 30, 2016

Appendix 4C - Strong Cash Position

March 30, 2016

Positive Heart Failure Trial Results Presented to AHA

March 30, 2016

MSB and Lonza form strategic global manufacturing alliance

March 30, 2016

Licensing Executives Society Deals of Distinction Award

March 30, 2016

Intervertebral Disc Repair Phase 2 Trial Update

March 30, 2016

First Minimally Invasive Procedure for Lumbar Disc Repair

March 30, 2016

First European Trial for Heart Attack Treatment Cleared

March 30, 2016

FDA Clearance for Phase 3 Bone Marrow Transplant Trial

March 30, 2016

FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes

March 30, 2016

Clearance for First Phase 2 Clinical Trial for Eye Diseases

March 30, 2016

Response to ASXPrice Query

March 30, 2016

Price Query

March 30, 2016

Positive Results in Phase 2 Lumbar Spinal Fusion Trial

March 30, 2016

MSB Provides Corporate Strategy For Neurologic Product

March 30, 2016

Mesoblast Corporate Overview - CEO Message to AGM

March 30, 2016

Key mpc patents granted in united states and china

March 30, 2016

Half-Year Results & Strategic Update on Product Development

March 30, 2016

Response to ASX price query

March 30, 2016

Positive Disc Repair Results Using Mesoblast Stem Cells

March 30, 2016

New Japanese Regenerative Medicine Legislation

March 30, 2016

MSBs Registration Plans for GVHD Cell Product in Japan

March 30, 2016

MSB Receives $4.3M Pipeline Funds from Australian Government

March 30, 2016

MPCs Strengthen Cardiac Function in End-Stage Heart Failure

March 30, 2016

MPCs Induce Functional Recovery in Ischemic Stroke Model

March 30, 2016

Mesoblast Reports Positive Type 2 Diabetes Trial Results

March 30, 2016

Mesoblast provides update on clinical programs of prochymal

March 30, 2016

Mesoblast, Intrexon and Ziopharm to Target Cancers

March 30, 2016

Mesoblast Acquires Osiris Cultured Stem Cell Business

March 30, 2016

Key European Patent Granted for Mesoblasts MPCs

March 30, 2016

MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure

March 30, 2016

MSB Accelerates Plans for Commercial Manufacturing Operation

March 30, 2016

Mesoblast Receives $5.05m for Stem Cell Pipeline Development

March 30, 2016

Circulation Publishes Improved Outcomes with Mesoblast Cells

March 30, 2016

Key US Patent Granted For Treatment Of Rheumatoid Arthritis

March 23, 2016

GVHD Product Launched In Japan

February 24, 2016

Increased Survival Using MSB Cells In Children With aGVHD

February 21, 2016

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.